Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026

BOULDER, Colo., May 12, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2026, at 10:00 am ET.

PRNewsWire • May 12, 2026

Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications

–  Announced positive long-term sevasemten data demonstrating sustained functional stabilization in Becker muscular dystrophy (Becker) up to 3.5 years of follow-up – –  CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in Q2 2026 – –  Pivotal GRAND CANYON results for sevasemten in Becker expected in Q4 2026 – BOULDER, Colo., May 7, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2026 and recent business highlights.

PRNewsWire • May 7, 2026

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo., May 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on April 30, 2026, Edgewise granted inducement stock options to purchase a total of 266,000 shares of Edgewise's common stock to 9 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").

PRNewsWire • May 4, 2026

Why Edgewise Therapeutics Stock Topped the Market on Tuesday

She raised her price target by $11 per share. In her view, the company's No.

The Motley Fool • Mar 17, 2026

Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up

–The MESA data show stabilization of function in participants on sevasemten versus the predicted functional decline observed in Becker natural history studies – – Data reinforce prior clinical findings of sevasemten in Becker, a rare disease with no approved treatments – –The GRAND CANYON placebo-controlled pivotal cohort is on track to readout in 4Q 2026 – BOULDER, Colo., March 10, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today presented at the 2026 MDA Clinical and Scientific Conference, long-term data from its MESA open-label extension study of sevasemten in Becker muscular dystrophy (Becker), a devastating genetic disorder with no approved therapeutic interventions.

PRNewsWire • Mar 10, 2026

Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026

BOULDER, Colo., March 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026, at 1:40 p.m.

PRNewsWire • Mar 4, 2026

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference

BOULDER, Colo., March 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference.

PRNewsWire • Mar 3, 2026

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs

–  CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026  – –  Phase 1 healthy adult trial data of EDG-15400 and plans for heart failure studies expected in H1 2026  – –  Pivotal GRAND CANYON results for sevasemten in Becker muscular dystrophy (Becker) expected in Q4 2026  – BOULDER, Colo., Feb. 26, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year of 2025 and recent business highlights.

PRNewsWire • Feb 26, 2026

Why Edgewise Therapeutics Stock Crushed the Market on Monday

One of the more bullish analysts tracking the company reiterated her enthusiastic buy recommendation on the biotech. She has flagged it as one of her firm's best stock ideas for this year.

The Motley Fool • Feb 10, 2026

Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026

BOULDER, Colo., Feb. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Behrad Derakhshan, Ph.D.

PRNewsWire • Feb 5, 2026